natgillin/translations-raw huggingface dataset:
In vitro and in vivo losartan and its pharmacologically active carboxylic acid metabolite E-3174 block all physiologically relevant actions of angiotensin II, regardless of the source or route of its synthesis.
In vitro in in vivo losartan in njegov farmakološko aktivni karboksikislinski presnovek E- 3174 blokirata vse fiziološko pomembne učinke angiotenzina II, ne glede na njegov izvor ali sintezno pot.
Losartan does not have an agonist effect nor does it block other hormone receptors or ion channels important in cardiovascular regulation.
Losartan nima agonističnega učinka niti ne zavira drugih hormonskih receptorjev ali ionskih kanalov, pomembnih za srčno- žilno regulacijo.
During the administration of losartan the removal of the angiotensin II negative feedback on renin secretion leads to increased plasma-renin activity (PRA).
Povečana aktivnost renina v plazmi povzroči zvečanje
Increase in the PRA leads to an increase in angiotensin II in plasma.
29 koncentracije angiotenzina II v plazmi.
After the discontinuation of losartan, PRA and angiotensin II values fell within 3 days to the baseline values.
Po prekinitvi zdravljenja z losartanom so aktivnost renina v plazmi in vrednosti angiotenzina II v 3 dneh padle na začetne vrednosti.
The active metabolite is 10- to 40-times more active than losartan on a weight for weight basis.
Aktivni presnovek je 10 - do 40- krat bolj aktiven kot losartan (v isti količini).
In addition, in an overall analysis of 16 double-blind clinical trials in 4131 patients, the incidence of spontaneously reported cough in patients treated with losartan was similar (3.1%) to that of patients treated with placebo (2.6%) or hydrochlorothiazide (4.1%), whereas the incidence with ACE inhibitors was 8.8%.
Poleg tega je skupna analiza 16 dvojno slepih kliničnih preizkušanj s 4. 131 bolniki pokazala, da je bila pojavnost kašlja iz spontanih poročil pri bolnikih, zdravljenih z losartanom, podobna (3, 1%) kot pri bolnikih, ki so prejemali placebo (2, 6%) ali hidroklorotiazid (4, 1%), medtem ko je bila pojavnost pri zaviralcih ACE 8, 8%.
Generally losartan causes a decrease in serum uric acid (usually < 0.4 mg/ dL) which was persistent in chronic therapy.
Ta učinek je bil pri kronični terapiji trajen.
Measurements of blood pressure 24 hours post-dose relative to 5 – 6 hours post-dose demonstrated blood pressure reduction over 24 hours; the natural diurnal rhythm was retained.
Meritve krvnega tlaka 24 ur po odmerku so v primerjavi z meritvami 5 - 6 ur po odmerku pokazale 24 urno znižanje krvnega tlaka; ohranjen je bil naravni vsakodnevni ritem.
Blood pressure reduction at the end of the dosing interval was 70 – 80% of the effect seen 5-6 hours post- dose.
Znižanje krvnega tlaka ob koncu odmernega intervala je znašalo približno 70- 80% učinka, ki so ga opazili 5- 6 ur po odmerku.
31 Losartan is equally effective in males and females, and in younger (below the age of 65 years) and older hypertensive patients.
Losartan je enako učinkovit pri zdravljenju bolnikov s hipertenzijo moškega in ženskega spola, tako mlajših (mlajših od 65 let) kot starejših.
LIFE Study The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study was a randomised, triple-blind, active-controlled study in 9193 hypertensive patients aged 55 to 80 years with ECG- documented left ventricular hypertrophy.
Študija LIFE Študija LIFE (Losartan Intervention For Endpoint Reduction in Hypertension; Zdravljenje z losartanom za zmanjšanje končnih opazovanih dogodkov pri bolnikih s hipertenzijo) je bila randomizirana, trojno slepa študija s primerjalnim zdravilom.
If goal blood pressure (< 140/ 90 mmHg) was not reached, hydrochlorothiazide (12.5 mg) was added first and, if needed, the dose of losartan or atenolol was then increased to 100 mg once daily.
Če ciljnega krvnega tlaka (< 140/ 90 mmHg) niso dosegli, so najprej dodali hidroklorotiazid (12, 5 mg), potem pa so, če je bilo potrebno, povečali odmerek losartana ali atenolola na 100 mg enkrat na dan.
Other antihypertensives, with the exception of ACE inhibitors, angiotensin II antagonists or beta-blockers were added if necessary to reach the goal blood pressure.
Za doseg ciljnega krvnega tlaka so, če je bilo potrebno, dodali še druge antihipertenzive, razen zaviralcev ACE, antagonistov angiotenzina II ali beta zaviralcev.
The mean length of follow up was 4.8 years.
Spremljanje je povprečno trajalo 4, 8 let.
The primary endpoint was the composite of cardiovascular morbidity and mortality as measured by a reduction in the combined incidence of cardiovascular death, stroke and myocardial infarction.
30 Primarni opazovani dogodek sta predstavljali srčno- žilna obolevnost in smrtnost, merjeni z zmanjšanjem kombinirane pojavnosti smrti zaradi srčno- žilnih zapletov, možganske kapi in miokardnega infarkta.
Treatment with losartan resulted in a 13.0% risk reduction (p=0.021, 95% confidence interval 0.77-0.98) compared with atenolol for patients reaching the primary composite endpoint.
Zdravljenje z losartanon je v primerjavi z atenololom tveganje za primarni sestavljeni opazovani dogodek zmanjšalo za 13, 0% (p = 0, 021; 95- odstotni interval zaupanja 0, 77- 0, 98).
Treatment with losartan reduced the risk of stroke by 25% relative to atenolol (p=0.001 95% confidence interval 0.63-0.89).
Zdravljenje z losrtanom je v primerjavi z atenololom zmanjšalo tveganje za možgansko kap za 25% (p=0, 001 95- odstotni interval zaupanja 0, 63- 0, 89).
The rates of cardiovascular death and myocardial infarction were not significantly different between the treatment groups.
Deleži smrti zaradi srčno- žilnih vzrokov in miokardnega infarkta med obema skupinama niso bili pomembno različni.
Hydrochlorothiazide
Hidroklorotizid
The renin-aldosterone link is mediated by angiotensin II and therefore coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics.
Zanko renin- aldosteron uravnava angiotenzin II, zato sočasna uporaba antagonista receptorjev angiotenzina II zaustavi izgubo kalija, povezano s tiazidnimi diuretiki.
After oral use, diuresis begins within 2 hours, peaks in about 4 hours and lasts about 6 to 12 hours the antihypertensive effect persists for up to 24 hours.
Antihipertenzivni učinek traja do 24 ur.
Losartan Following oral administration, losartan is well absorbed and undergoes first-pass metabolism, forming an active carboxylic acid metabolite and other inactive metabolites.
Losartan Po peroralnem zaužitju se losartan dobro absorbira in je podvržen presnovi prvega prehoda, kjer nastajajo aktivni karboksikislinski presnovek in ostali neaktivni presnovki.
The systemic bioavailability of losartan tablets is approximately 33%.
Sistemska biološka uporabnost losartana je približno 33%.
Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively.
3- 4 urah.
Losartan Both losartan and its active metabolite are ≥ 99% bound to plasma proteins, primarily albumin.
Losartan Tako losartan kot njegov aktivni presnovek sta v ≥ 99% vezana na plazemske proteine, predvsem na albumin.
Studies in rats indicate that losartan crosses the blood- brain barrier poorly, if at all.
Raziskave na podganah kažejo, da losartan v zelo majhnem deležu, če sploh, prehaja skozi krvno- možgansko bariero.
32 Hydrochlorothiazide Hydrochlorothiazide crosses the placental but not the blood-brain barrier and is excreted in breast milk.
Izloča se v materinem mleku.
Losartan About 14% of an intravenously- or orally-administered dose of losartan is converted to its active metabolite.
Losartan Približno 14% intravensko ali peroralno danega odmerka losartana se pretvori v njegov aktivni presnovek.
In addition to the active metabolite, inactive metabolites are formed, including two major metabolites formed by hydroxylation of the butyl side chain and a minor metabolite, an N-2 tetrazole glucuronide.
Poleg aktivnega metabolita se tvorijo tudi neaktivni presnovki, vključno z dvema večjima, ki nastaneta s hidroksilacijo butilne stranske verige, in enim manjšim, N- 2 tetrazol glukuronidom.
Elimination
31 Izločanje
Losartan Plasma clearance of losartan and its active metabolite is about 600 mL/ min and 50 mL/ min, respectively.
Losartan Plazemski očistek losartana je približno 600 ml/ min, njegovega aktivnega presnovka pa 50 ml/ min.
Renal clearance of losartan and its active metabolite is about 74 mL/ min and 26 mL/ min, respectively.
Renalni očistek losartana je 74 ml/ min, njegovega aktivnega presnovka pa 26 ml/ min.
When losartan is administered orally, about 4% of the dose is excreted unchanged in the urine, and about 6% of the dose is excreted in the urine as active metabolite.
Po peroralnem odmerku losartana se približno 4% zaužitega odmerka izloči v urin nespremenjenega, približno 6% zaužitega odmerka pa v obliki aktivnega presnovka.
Following oral administration, plasma concentrations of losartan and its active metabolite decline polyexponentially with a terminal half-life of about 2 hours and 6-9 hours, respectively.
Po peroralnem zaužitju plazemske koncentracije losartana in njegovega aktivnega presnovka padajo polieksponentno, pri čemer je končni razpolovni čas losartana približno 2 uri, njegovega aktivnega presnovka pa 6- 9 ur.
During once- daily dosing with 100 mg, neither losartan nor its active metabolite accumulates significantly in plasma.
Pri enkrat dnevnem odmerjanju 100 mg se niti losartan niti njegov aktivni presnovek v plazmi ne kopičita pomembno.
Following an oral dose of 14C-labeled losartan in man, about 35% of radioactivity is recovered in the urine and 58% in the feces.
Po peroralnem/ intravenskem odmerku s 14C označenega losartana pri človeku najdemo približno 35% radioaktivnosti v urinu, 58% pa v blatu.
Hydrochlorothiazide Hydrochlorothiazide is not metabolized but is eliminated rapidly by the kidney.
Hidroklorotiazid Hidroklorotiazid se ne presnavlja, ampak se hitro izloči skozi ledvice.
When plasma levels have been followed for at least 24 hours, the plasma half-life has been observed to vary between 5.6 and 14.8 hours.
Po najmanj 24- urnem spremljanju plazemske koncentracije so opazili spremenljiv plazemski razpolovni čas od 5, 6 do 14, 8 ur.
At least 61 percent of the oral dose is eliminated unchanged within 24 hours.
Vsaj 61% peroralnega odmerka se izloči nespremenjenega v 24 urah.
Losartan-Hydrochlorothiazide The plasma concentrations of losartan and its active metabolite and the absorption of hydrochlorothiazide in elderly hypertensives are not significantly different from those in young hypertensives.
Losartan- hidroklorotiazid Plazemske koncentracije losartana in njegovega aktivnega presnovka ter absorbcija hidroklorotiazida pri starejših hipertonikih niso bile pomembno drugačne od tistih pri mladih moških hipertonikih.
Losartan Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of losartan and its active metabolite were, respectively, 5-fold and 1.7-fold greater than those seen in young male volunteers.
1, 7- krat večje od tistih pri mladih moških prostovoljcih.
The toxic potential of the combination of
Toksični potencial kombinacije losartan/ hidroklorotiazd so ovrednotili v študijah kronične toksičnosti, ki so trajale do šest mesecev, pri podganah in psih, ki so jim kombinacijo dajali peroralno.
33 losartan/ hydrochlorothiazide was evaluated in chronic toxicity studies for up to six months duration in rats and dogs after oral administration, and the changes observed in these studies with the combination were mainly produced by the losartan component.
Spremembe, ki so jih opazili v teh študijah s kombinacijo, so bile večinoma zaradi losartana.
The administration of the losartan/ hydrochlorothiazide combination induced a decrease in the red blood cell parameters (erythrocytes, haemoglobin, haematocrit), a rise in urea-N in the serum, a decrease in heart weight (without a histological correlate) and gastrointestinal changes (mucous membrane lesions, ulcers, erosions, haemorrhages).
Uporaba kombinacije losartan/ hidroklorotiazid je povzročila zmanjšanje eritrocitnih indeksov (števila eritrocitov, hemoglobina, hematokrita) in povečanje količine N- sečnine v serumu, zmanjšanje teže srca (brez histološke povezave) in spremembe v prebavilih (lezije, ulkusi, erozije in krvavitve mukozne membrane).
There was no evidence of teratogenicity in rats or rabbits treated with the losartan/ hydrochlorothiazide combination.
Pri podganah ali kuncih, ki so prejemali kombinacijo losartan/ hidroklorotiazid, niso odkrili teratogenosti.
As observed in studies with losartan alone, adverse foetal and neonatal effects, including renal toxicity and foetal death, occurred when pregnant rate were treated with the losartan/ hydrochlorothiazide combination during late gestation and/ or lactation.
Kot so opazili v študijah s samim losartanom, so se neželeni fetalni in neonatalni učinki, ki so vključevali neželene učinke na ledvice in smrt ploda, pojavili, če so breje podgane prejemale kombinacijo losartan/ hidroklorotiazid med visoko brejostjo in/ ali dojenjem.
Cozaar Comp 50 mg/ 12.5 mg, Cozaar Comp 100 mg/ 12.5 mg and Cozaar Comp 100 mg/ 25 mg:
Cozaar Comp 50 mg/ 12, 5 mg, Cozaar Comp 100 mg/ 12, 5 mg in Cozaar Comp 100 mg/ 25 mg:
Each tablet contains the following inactive ingredients: microcrystalline cellulose(E460), lactose monohydrate, pregelatinized maize starch, magnesium stearate (E572), hydroxypropyl cellulose (E463), hypromellose(E464).
Vsaka tableta vsebuje naslednje pomožne snovi: mikrokristalno celulozo (E460), laktozo monohidrat, predgelirani koruzni škrob, magnezijev stearat (E572), hidroksipropilcelulozo (E463), hipromelozo (E464).
Cozaar Comp 50 mg/ 12.5 mg contains 4.24 mg (0.108 mEq) of potassium.
Cozaar Comp 50 mg/ 12, 5 mg vsebuje 4, 24 mg (1, 108 mEq) kalija.
Cozaar Comp 100 mg/ 12.5 mg mg contains 8.48 mg (0.216 mEq) of potassium. and Cozaar Comp 100 mg/ 25 mg contains 8.48 mg (0.216 mEq) of potassium.
Cozaar Comp 100 mg/ 25 mg vsebuje 8, 48 mg (0, 216 mEq) kalija.
Cozaar Comp 50 mg/ 12.5 mg and Cozaar Comp 100 mg/ 25 mg also contain, Titanium dioxide (E171), Quinoline yellow aluminum lake (E104), and Carnauba wax (E903)
Cozaar Comp 50 mg/ 12, 5 mg in Cozaar Comp 100 mg/ 25 mg lahko vsebujeta še titanov dioksid (E171), kinolinsko rumeno (E104) in karnauba vosek (E903).
Carnauba wax (E903), Titanium dioxide (E171)
Cozaar Comp 100 mg/ 12, 5 mg vsebuje tudi: koncentrat bele barve [ali posamezne sestavine koncentrata: hidroksipropilcelulozo (E463), hipromelozo (E464) in titanov dioksid (E171)] in karnauba vosek (E903).
34 Store in the original package.
Shranjujte v originalni ovojnini.
Keep the blister in the outer carton and the keep the bottle tightly closed.
Plastenko shranjujte tesno zaprto.
Cozaar Comp 50 mg/ 12.5 mg - PVC/ PE/ PVDC blister packages with aluminum foil lidding in packs of 4, 7, 10, 14, 20, 28, 30, 50, 56, 84, 98, or 280 tablets.
Cozaar Comp 50 mg/ 12, 5 mg - PVC/ PE/ PVDC pretisni omoti s prevleko iz aluminijaste folije v pakiranjih po 4, 7, 10, 14, 20, 28, 30, 50, 56, 84, 98 ali 280 tablet.
Cozaar Comp 100 mg/ 12.5 mg - PVC/ PE/ PVDC blister packages with aluminum foil lidding in packs of 14, 15, 28, 30, 50, 56, 84, 90, 98, 280 tablets.
Cozaar Comp 100 mg/ 12, 5 mg - PVC/ PE/ PVDC pretisni omoti s prevleko iz aluminijaste folije v pakiranjih po 14, 15, 28, 30, 50, 56, 84, 90, 98, 280 tablet.
Cozaar Comp 100 mg/ 25 mg > - PVC/ PE/ PVDC blister packages with aluminum foil lidding in packs of 7, 14, 28, 30, 50, 56, 84, 90, 98, or 280 tablets.
Cozaar Comp 100 mg/ 25 mg - PVC/ PE/ PVDC pretisni omoti s prevleko iz aluminijaste folije v pakiranjih po 7, 14, 28, 30, 50, 56, 84, 90, 98 ali 280 tablet.
6.6 Special precautions for disposal< and other handling >
33 6. 6 Posebni varnostni ukrepi za odstranjevanje
No special requirements.
Nobenih posebnih zahtev.
< {DD/MM/YYYY} > < {DD month YYYY} >
{DD/ MM/ LLLL}
35 LABELLING
35 PODATKI NA ZUNANJI OVOJNINI
Outer carton for Cozaar Comp 50 mg/ 12.5 mg film-coated tablets blister
Škatla s pretisnimi omoti za Cozaar Comp 50 mg/ 12, 5 mg filmsko obložene tablete
Cozaar Comp 50 mg/ 12.5 mg mg film-coated tablets
Cozaar Comp 50 mg/ 12, 5 mg filmsko obložene tablete
Losartan and hydrochlorothiazide
losartan in hidroklorotiazid
Each tablet contains 50 mg losartan potassium and 12.5 mg hydrochlorothiazide.
Vsaka tableta vsebuje 50 mg kalijevega losartanata in 12, 5 mg hidroklorotiazida.
4, 7, 10, 14, 20, 28, 30, 50, 56, 84, 98, or 280 film-coated tablets.
4, 7, 10, 14, 20, 28, 30, 50, 56, 84, 98 ali 280 filmsko obloženih tablet.
[To be completed nationally] [For referral procedures]
[Izpolni država članica]
38 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
37 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Blister for Cozaar Comp 50 mg/ 12.5 mg film-coated tablets
Pretisni omot za Cozaar Comp 50 mg/ 12, 5 mg filmsko obložene tablete
[See Annex I - To be completed nationally] [For referral procedures]
[Glejte Dodatek I - Izpolni država članica]
Outer carton for Cozaar Comp 50 mg/ 12.5 mg film-coated tablets HDPE Bottle
Škatla s HDPE plastenko za Cozaar Comp 50 mg/ 12, 5 mg filmsko obložene tablete
Bottle label for Cozaar Comp 50 mg/ 12.5 mg film-coated tablets HDPE Bottle
Nalepka za HDPE plastenko za Cozaar Comp 50 mg/ 12, 5 mg filmsko obložene tablete
N/ A
Navedba ni potrebna.
Outer carton for Cozaar Comp 100 mg/ 12.5 mg film-coated tablets blister
Škatla s pretisnimi omoti za Cozaar Comp 100 mg/ 12, 5 mg filmsko obložene tablete
Cozaar Comp 100 mg/ 12.5 mg mg film-coated tablets
Cozaar Comp 100 mg/ 12, 5 mg filmsko obložene tablete
Each tablet contains 100 mg losartan potassium and 12.5 mg hydrochlorothiazide.
Vsaka tableta vsebuje 100 mg kalijevega losartanata in 12, 5 mg hidroklorotiazida.
Lactose-monohydrate.
Laktoza monohidrat.
14, 15, 28, 30, 50, 56, 84, 90, 98, or 280 film coated-tablets.
14, 15, 28, 30, 50, 56, 84, 90, 98 ali 280 filmsko obloženih tablet.
[To be completed nationally][For referral procedures]
[Izpolni država članica]
45 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
44 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Blister for Cozaar Comp 100 mg/ 12.5 mg film-coated tablets
Pretisni omot za Cozaar Comp 100 mg/ 12, 5 mg filmsko obložene tablete
[See Annex I - To be completed nationally] [For referral procedures]
[Glejte dodatek 1 – Izpolni država članica]
46 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
45 PODATKI NA ZUNANJI OVOJNINI
Outer carton for Cozaar Comp 100 mg/ 12.5 mg film-coated tablets HDPE bottle
Škatla s HDPE plastenko za Cozaar Comp 100 mg/ 12, 5 mg filmsko obložene tablete
100 film coated-tablets.
100 filmsko obloženih tablet.
48 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
47 PODATKI NA ZUNANJI OVOJNINI
Bottle label for Cozaar Comp 100 mg/ 12.5 mg film-coated tablets HDPE bottle
Nalepka za HDPE plastenko za Cozaar Comp 100 mg/ 12, 5 mg filmsko obložene tablete
Outer carton for Cozaar Comp 100 mg/ 25 mg film-coated tablets blister
Škatla za Cozaar Comp 100 mg/ 25 mg filmsko obložene tablete
Cozaar Comp 100 mg/ 25 mg mg film-coated tablets
Cozaar Comp 100 mg/ 25 mg filmsko obložene tablete
Each tablet contains 100 mg losartan potassium and 25 mg hydrochlorothiazide.
Vsaka tableta vsebuje 100 mg kalijevega losartanata in 25 mg hidroklorotiazida
7, 14, 28, 30, 50, 56, 84, 90, 98, or 280 film-coated tablets
7, 14, 28, 30, 50, 56, 84, 90, 98 ali 280 filmsko obloženih tablet.
51 11.
50 11.
52 MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS
51 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA PRETISNEM OMOTU ALI DVOJNEM TRAKU
Blister for Cozaar Comp 100 mg/ 25 mg film-coated tablets
Pretisni omot za Cozaar Comp 100 mg/ 25 mg filmsko obložene tablete
53 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
52 PODATKI NA ZUNANJI OVOJNINI
Outer carton for Cozaar Comp 100 mg/ 25 mg film-coated tablets HDPE bottle
Škatla s HDPE plastenko za Cozaar Comp 100 mg/ 25 mg filmsko obložene tablete
Each tablet contains 100 mg losartan potassium and 25 mg hydrochlorothiazide.
Vsaka tableta vsebuje 100 mg kalijevega losartanata in 25 mg hidroklorotiazida.
55 PARTICULARS TO APPEAR ON THE OUTER PACKAGING
54 PODATKI NA ZUNANJI OVOJNINI
Outer carton for Cozaar Comp 100 mg/ 25 mg film-coated tablets HDPE bottle
Nalepka za HDPE plastenko za Cozaar Comp 100 mg/ 25 mg filmsko obložene tablete
N/ A
56 NAVODILO ZA UPORABO
Read all of this leaflet carefully before taking this medicine.
Pred uporabo natančno preberite navodilo! • Navodilo shranite.
You may need to read it again. • If you have any further questions, ask your doctor or your pharmacist. • This medicine has been prescribed for you.
Morda ga boste želeli ponovno prebrati. • Če imate dodatna vprašanja, se posvetujte z zdravnikom ali s farmacevtom. • Zdravilo je bilo predpisano vam osebno in ga ne smete dajati drugim.
It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.
Njim bi lahko celo • škodovalo, čeprav imajo znake bolezni, podobne vašim. • Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika ali farmacevta.
What Cozaar Comp is and what it is used for 2.
Kaj je zdravilo Cozaar Comp in za kaj ga uporabljamo 2.
Before you take Cozaar Comp 3.
Kaj morate vedeti, preden boste vzeli zdravilo Cozaar Comp 3.
How to take Cozaar Comp 4.
Kako jemati zdravilo Cozaar Comp 4.
How to store Cozaar Comp 6.
Shranjevanje zdravila Cozaar Comp 6.
WHAT COZAAR COMP IS AND WHAT IT IS USED FOR
KAJ JE ZDRAVILO COZAAR COMP IN ZA KAJ GA UPORABLJAMO
Cozaar Comp is a combination of an angiotensin II receptor antagonist (losartan) and a diuretic (hydrochlorothiazide).
Zdravilo Cozaar Comp je kombinacija antagonista angioetnzina II (losartana) in diuretika (hidroklorotiazida).
BEFORE YOU TAKE COZAAR COMP
KAJ MORATE VEDETI, PREDEN BOSTE VZELI ZDRAVILO COZAAR COMP
• if you are allergic (hypersensitive) to losartan, hydrochlorothiazide or to any of the other ingredients in this medicine. • if you are allergic (hypersensitive) to other sulfonamide-derived substances (e. g. other thiazides, some antibacterial drugs such as co-trimoxazole, ask your doctor if you are not sure) • if you are, think you may be or are planning to become pregnant (see also “ Pregnancy and breast-feeding”) • if you are breast-feeding • if you have severely impaired liver function • if you have severely impaired kidney function or your kidneys are not producing any urine. • if you have low potassium, low sodium or high calcium levels which cannot be corrected by treatment • if you are suffering from gout
• če ste alergični na (preobčutljivi za) losartan, hidroklorotiazid ali katerokoli sestavino zdravila. • če ste alergični na (preobčutljivi za) druge derivate sulfonamida (npr. druge tiazide, nekatera protibakterijska zdravila, kot je ko- trimoksazol; če niste prepričani, vprašajte zdravnika). • če ste noseči, mislite, da ste noseči, ali če nameravate zanositi (glejte tudi poglavje "Nosečnost in dojenje"). • če dojite. • če imate hudo okvaro jeter. • če imate hudo okvaro ledvic ali vaše ledvice ne tvorijo urina. • če imate nizko vrednost kalija, nizko vrednost natrija ali visoko vrednost kalcija, ki se jih ne da pozdraviti. • če imate protin.
Take special care with Cozaar Comp
Bodite posebno pozorni pri jemanju zdravila Cozaar Comp
• if you have previously suffered from swelling of the face, lips, throat or tongue
• če so vam kdaj otekali obraz, ustnice, žrelo ali jezik. • če jemljete diuretike (tablete za odvajanje vode). • če ste na dieti s hrano z zmanjšano količino soli. • če ste močno bruhali in/ ali imeli hudo drisko. • če imate srčno popuščanje. • če imate zožane arterije, ki vodijo do ledvic (stenoza ledvične arterije) ali vam deluje samo ena ledvica ali pa so vam pred kratkim presadili ledvico.